Why Is Cannabis Drug Testing Important?
Cannabis is becoming more widely available across the world. Several countries now permit its use for medical or non-medical purposes. As access grows, many people want to understand how cannabis use might show up on a drug test.
Urine testing is one of the most common ways to screen for cannabis use. These tests are used in workplaces, competitive sport, and other settings such as the criminal justice system. For patients prescribed cannabis-based medicines, understanding how their medication may affect test results can be an important practical concern.
A recent systematic review, published in Pharmacological Research in 2026, looked at data from 92 studies. It examined how different patterns of cannabis use may affect the levels of tetrahydrocannabinol (THC) and its metabolites in urine. The findings help to shed light on the risk of a positive test under different circumstances.
What Do Cannabis Urine Tests Actually Measure?
Most cannabis urine tests look for a substance called 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (11-COOH-THC). This is the final breakdown product of THC, the main active compound in cannabis. Your liver creates 11-COOH-THC as it processes THC. The substance is then passed out of the body through urine.
It is important to note that 11-COOH-THC levels in urine do not reliably indicate whether someone is currently impaired by cannabis. A positive urine test shows that cannabis has been used at some point, but it does not tell us whether the person is affected at the time of the test.
What Thresholds Are Used in Drug Testing?
Different organisations use different cut-off levels to define a positive test. The threshold chosen depends on the purpose of the test.
Workplace Testing
In workplace settings, urine testing usually follows two steps. First, a quick screening test is carried out. If that test is not clearly negative, a more detailed laboratory analysis follows. The screening cut-off is typically 50 ng/mL. The confirmatory cut-off used in most workplace standards, including the European Workplace Drug Testing Society (EWDTS) guidelines, is 15 ng/mL of 11-COOH-THC.
Competitive Sport
The World Anti-Doping Agency (WADA) uses a higher threshold. Their Decision Limit is set at 180 ng/mL of 11-COOH-THC. This level was raised from 15 ng/mL in 2013. The change was made to reduce the chance of detecting cannabis used outside of competition.
Other Settings
Drug testing may also take place in the criminal justice system or rehabilitation programmes. These settings often follow workplace thresholds. However, some may use stricter cut-offs, such as a screening level of 20 ng/mL.
What Did the Research Find?
The review looked at three types of data: studies where cannabis was given to participants in controlled settings, studies of regular cannabis users, and studies that tracked cannabis users during a period when they stopped using.
How Might a Single Dose Affect Test Results?
Very low doses (up to 1 mg THC): The review found that very low oral doses of THC only rarely produced urine levels above workplace thresholds. While occasional readings above 15 ng/mL were reported, these were sporadic. Mean concentrations generally stayed well below the threshold. These doses appear unlikely to trigger a positive result through the standard two-stage testing process.
Low doses (1–5 mg THC): Single doses in this range occasionally produced levels above the 50 ng/mL screening cut-off, particularly when cannabis was inhaled through vaporisation. Oral THC appeared to produce higher metabolite levels, likely because of how the body processes it through the liver. The evidence suggests that single doses at the upper end of this range may carry some risk of triggering a positive workplace test.
Moderate doses and the WADA threshold: The lowest dose reported to exceed the 180 ng/mL WADA limit was 10 mg of oral THC. For inhaled cannabis, higher doses of around 15–20 mg were needed to reach this level. However, the mean concentrations in these studies were often much lower than the maximum values observed. This suggests these dose levels may represent the point at which the risk of exceeding the anti-doping threshold begins to emerge.
How Might Repeated Doses Affect Test Results?
When cannabis was taken repeatedly, even very low doses appeared to carry a greater risk of exceeding thresholds compared with a single dose.
Repeated trace doses (under 1 mg per day) occasionally exceeded the 15 ng/mL confirmatory threshold. However, results were not consistent across all studies. Repeated low doses (1–5 mg per day) showed a clearer ability to exceed screening levels, though much of this evidence came from small studies. Repeated moderate doses (above 3 mg per day) appeared very likely to produce levels above workplace thresholds and may also produce concentrations above the WADA limit.
The review also noted that topical cannabis products appeared to pose minimal risk. One study found very low urine metabolite levels even after daily topical application of over 8 mg THC.
What About Regular Cannabis Use?
Among the 37 studies of cannabis consumers, almost all reported average 11-COOH-THC levels above the 15 ng/mL confirmatory threshold. Those who did not exceed this level tended to be infrequent users (using once or twice a month, or less) or people who used CBD-only products.
Higher frequency use was associated with higher metabolite levels. The review reported that weekly users had mean concentrations around 547 ng/mL when tested 12–25 hours after use. People who used cannabis roughly four to five times per week showed average levels of around 315 ng/mL up to approximately four and a half days after use.
Users who consumed cannabis infrequently, used CBD-only products, or abstained for at least 12 hours before testing were generally less likely to produce positive workplace results.
The review highlighted considerable variation between individuals. Factors such as dose, how cannabis is taken, the potency of the product, and a person’s own metabolism may all influence urine metabolite levels. The figures described here represent averages across study populations and may not reflect any one person’s experience.
How Long Might It Take for Levels to Drop After Stopping?
Seventeen studies tracked cannabis users during a period of stopping use. The findings suggest that 11-COOH-THC can remain above the 15 ng/mL workplace threshold for several weeks after a person stops using cannabis. The time needed varied widely, from around 17 to 84 days, depending on how high the levels were before stopping.
In studies where abstinence was confirmed through testing, average levels typically fell from around 160–230 ng/mL to below 15 ng/mL within roughly 17 to 28 days. However, some individuals experienced temporary rebounds during this period.
For the WADA threshold, the picture was more encouraging. Most studies found that levels above 180 ng/mL dropped below this cut-off within about two to seven days of confirmed or reported cessation. People with very high starting levels may take longer.
What Are the Limitations of This Research?
As with any systematic review, there are important limitations to keep in mind when considering these findings.
Many included studies had small sample sizes and varied in quality. Observational findings cannot prove cause and effect. Individual results may differ significantly from the averages reported. Always discuss any concerns about drug testing with your prescribing clinician.
The review did not examine how individual factors such as age, sex, body composition, or genetics might influence urine metabolite levels. Many of the included studies used lower-potency cannabis products than those commonly available today. Higher-potency products may produce different results. Some of the data, particularly for low-dose and multi-dose findings, came from small studies or single participants. This means the findings at these dose levels should be treated with particular caution.
Additionally, the review focused on THC and its metabolites. Other cannabinoids, which may be relevant in some testing contexts such as sport, were not examined.
What Does This Mean for Patients Prescribed Medical Cannabis?
The number of patients accessing medical cannabis in the UK has been growing steadily since they were reclassified in 2018. For some patients, concerns about workplace drug testing are a practical consideration, particularly for those whose jobs involve driving or operating machinery.
This research suggests that the risk of a positive urine test may depend on several factors, including the THC dose, how the medicine is taken, how often it is used, and how much time has passed since the last dose. Patients who have concerns about drug testing should discuss these with their prescribing clinician, who can provide guidance based on their individual circumstances. It may also be helpful to have a conversation with occupational health or your employer as appropriate if you are prescribed medical cannabis so they may be aware of any reasonable adjustments they may need to make for you during the working day.
It is also worth remembering that a positive urine test does not indicate impairment. Medical cannabis should always be taken according to the guidance provided by your clinician.
Could You Be Eligible for a Consultation?
Cannabis-based medicines may be considered when other treatments have not provided adequate relief. If you would like to find out whether you could be eligible for a consultation with one of our specialist clinicians, you can complete our free online eligibility assessment.
